{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Status:
Investigational
Source:
NCT00608985: Phase 3 Interventional Completed Primary Insomnia
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Almorexant (ACT-078573) is an orally active dual orexin receptor antagonist that is being developed by Actelion Ltd, in collaboration with GlaxoSmithKline plc, for the treatment of primary insomnia. Almorexant is a first-in-class compound that targets the orexin system, which plays a key role in wake promotion and stabilization; In January 2011, GlaxoSmithKline (GSK) and Actelion Ltd announced that clinical development of Phase III of almorexant has been discontinued. This decision follows a review of data from additional clinical studies, which were conducted to further establish the clinical profile of almorexant, including the tolerability profile.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Carbazeran is a potent PDE-II and PDE-III inhibitor. Potently inhibits cAMP hydrolysis. Shows chronotropic and inotropic effect in vivo (EC50 = 100 μM, ionotropic effects, independent of adrenergic mechanisms). Carbazeran is a potent cardiac stimulant. Phosphodiesterase inhibition and elevation of intracellular cyclic AMP concentration may be involved, at least in part, in carbazeran`s cardiac effect.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Verilopam is a potent analgesic.
Status:
Investigational
Class (Stereo):
CHEMICAL (UNKNOWN)
FENIMIDE, a succinimide derivative, is an antipsychotic drug. It is not found in any pharmaceutical preparations sold in the US. It was found that FENIMIDE produced a sedative effect prior to deeper central nervous system depression.
Status:
Investigational
Source:
INN:butoprozine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Butoprozine increased the action potential duration like amiodarone, depressed the plateau phase like verapamil and decreased the amplitude and the maximum rate of depolarization. Butoprozine injected intravenously depressed sino-atrial node function, lengthened A-V nodal conduction time and the A-V nodal refractory period, and prolonged the atrial refractory period. Thus butoprozine acted preferentially on parts of the myocardial tissue where the slow inward current seems to be particularly involved. In this respect, butoprozine was more active than amiodarone, but in contrast to this drug, butoprozine did neither prolong the ventricular monophasic action potential duration nor the ventricular refractory period.
Status:
Investigational
Source:
INN:betamethadol [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Betamethadol or β-methadol is an opioid analgesic under international control according to the UN Single Convention 1961. Betamethadol is an isomer of the racemic mixture of dimepheptanol.
Class (Stereo):
CHEMICAL (RACEMIC)
Tinisulpride is a sulfamoylbenzoic acid patented by Fabre, Pierre, S. A. as an antiemetic agent.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Ethonam is an antifungal compound. Its activity was evaluated in the treatment of chronic athlete's foot.
Status:
Investigational
Source:
NCT01120600: Phase 3 Interventional Completed Osteoporosis
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor, an enzyme involved in bone resorption. Merck & Co was developing odanacatib, a once-weekly, oral Odanacatib, for the treatment of postmenopausal osteoporosis and osteoporosis in men. Merck & Co. has discontinued development of its cathepsin K inhibitor odanacatib, citing an increased risk of cardiovascular events for the osteoporosis drug.
Class (Stereo):
CHEMICAL (ACHIRAL)
Bisaramil, an antiarrhythmic drug was developed as an inhibitor of calcium transport and as a membrane stabilizer. In addition, the drug showed tonic and frequency-dependent block that is most potent against the heart Na+ channel. However, the phase-II for Arrhythmias in Japan was discontinued.
